Erucic acid is a monounsaturated omega-9 fatty acid found abundantly in the seed oils of plants in the mustard and brassica families, including rapeseed and mustard. Although it has long been viewed with caution in the food industry because of concerns about cardiac effects at very high intakes, recent research has begun to reveal a more nuanced picture. Prior work by some of the same authors and by other groups has suggested that erucic acid possesses antioxidant and anti-inflammatory properties, and studies in mice have indicated that erucic acid-rich oils can improve insulin resistance. The new study set out to test whether these properties translate into tangible protection for kidneys under sustained diabetic stress.

To model the disease, the researchers induced diabetes in rats with a single intraperitoneal injection of streptozotocin, a compound that selectively destroys the insulin-producing beta cells of the pancreas. Streptozotocin-induced diabetes is a well-established experimental platform for studying diabetic nephropathy because the resulting chronic hyperglycemia triggers many of the same metabolic and structural changes seen in human patients, including albumin leakage into the urine, elevated blood urea nitrogen, and progressive damage to the glomeruli and tubules. Once diabetes was established, the animals received erucic acid orally at doses of 10 or 20 milligrams per kilogram of body weight once daily for eight weeks, allowing the team to assess both short- and longer-term effects on metabolic control and renal health.

The metabolic results were striking. Rats treated with erucic acid showed significantly reduced blood glucose and glycated hemoglobin, or HbA1c, the long-term marker of blood sugar control. At the same time, the treatment raised circulating insulin and adiponectin—a hormone with insulin-sensitizing and anti-inflammatory actions—while lowering resistin, an adipokine implicated in insulin resistance and inflammation. The fatty acid also corrected the dyslipidemia that typically accompanies uncontrolled diabetes, reducing total cholesterol and triglycerides while raising protective high-density lipoprotein cholesterol. Because lipid abnormalities and poor glycemic control both feed the vicious cycle of kidney damage in diabetes, these systemic improvements likely contributed to the renal benefits observed downstream.

The most consequential findings concerned kidney function itself. Diabetic rats in the untreated group displayed the classic biochemical signature of nephropathy: elevated serum creatinine, elevated blood urea nitrogen, increased urinary albumin excretion, and increased 24-hour urine volume, all reflecting a failing filtration barrier. Erucic acid treatment reversed these trends in a dose-dependent manner, lowering creatinine and urea levels, reducing albumin loss, decreasing excessive urine output, and improving creatinine clearance—a direct measure of how effectively the kidneys filter waste from the blood. Histopathological examination of kidney tissue corroborated the biochemical data, showing preservation of renal architecture in treated animals compared with the structural deterioration evident in untreated diabetic controls.

Delving into mechanism, the researchers focused on oxidative stress, a central engine of diabetic kidney injury. Chronically high glucose floods the kidney with reactive oxygen species that overwhelm its antioxidant systems, damaging lipids, proteins, and DNA. In the diabetic rats, the activities of the key antioxidant enzymes superoxide dismutase and catalase, along with levels of the cellular antioxidant glutathione, were depleted. Erucic acid supplementation restored these defenses to near-normal levels. Consistently, markers of oxidative damage fell: malondialdehyde, a product of lipid peroxidation, and nitric oxide, which at pathological levels contributes to inflammatory tissue injury, were both significantly reduced in the kidneys of treated animals.

Inflammation provided the second mechanistic thread. Diabetic nephropathy is increasingly understood as an inflammatory disease in which immune cells and pro-inflammatory signaling molecules accelerate the scarring and functional decline of renal tissue. The study found that erucic acid downregulated the expression of the major pro-inflammatory cytokines tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 in kidney tissue. This anti-inflammatory shift parallels findings from the group’s earlier work, which showed that erucic acid could suppress inflammatory cytokine expression and NF-kappa B signaling in models of memory impairment and cancer, suggesting that the fatty acid acts on conserved inflammatory pathways that operate across multiple organ systems.

Particularly noteworthy was the effect on early injury biomarkers. Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin, known as KIM-1 and NGAL, are proteins whose expression rises sharply when tubular cells are under stress, often before conventional markers like creatinine begin to move. They are increasingly used in clinical research as sensitive harbingers of kidney damage. In the present study, erucic acid significantly decreased renal KIM-1 and NGAL levels, indicating that the compound not only preserves gross filtration function but also protects the tubular cells at the cellular level, potentially intercepting injury at an earlier stage of the disease process.

Complementing the laboratory experiments, the team performed in silico molecular docking studies to explore how erucic acid might interact with molecular targets implicated in diabetic nephropathy. These computational analyses, which model the binding of a small molecule to the three-dimensional structures of proteins, supported the idea that erucic acid can engage inflammatory and oxidative stress mediators directly, providing a structural rationale for the biochemical changes observed in the animals. While docking results are hypotheses rather than proof, they offer a roadmap for future mechanistic studies aimed at pinpointing the precise signaling pathways—such as NF-kappa B and related inflammatory cascades—through which the fatty acid exerts its effects.

The authors are careful to frame these results as preclinical. Findings in streptozotocin-induced rats do not automatically translate to human diabetic kidney disease, and questions about optimal dosing, long-term safety, and the cardiac considerations historically associated with erucic acid consumption will need to be addressed before any clinical application. Nevertheless, the convergence of improved glycemic control, corrected dyslipidemia, restored antioxidant capacity, suppressed inflammatory cytokines, reduced tubular injury markers, and preserved kidney architecture paints a coherent and encouraging picture. As the global burden of diabetes continues to climb, with hundreds of millions of people at risk of diabetic nephropathy, the identification of an accessible, naturally derived fatty acid with multi-pronged kidney protection offers a compelling new lead in the search for therapies that can keep diabetic kidneys working longer.

Subject of Research: Renoprotective effects of erucic acid in streptozotocin-induced diabetic nephropathy in rats

Article Title: Renoprotective effects of the erucic acid in experimental diabetic nephropathy: antioxidant, anti-inflammatory, and in silico insights

Article References: Eid, T. M., Al-Abbasi, F. A., Afzal, M., Bawadood, A. S., Albishi, H. M., Alzarea, S. I., Chaieb, K., Sayyed, N., & Kazmi, I. (2026). Renoprotective effects of the erucic acid in experimental diabetic nephropathy: antioxidant, anti-inflammatory, and in silico insights. 3 Biotech, 16(9), Article 404. https://doi.org/10.1007/s13205-026-05041-1

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05041-1

Keywords: erucic acid, diabetic nephropathy, oxidative stress, inflammation, kidney disease, antioxidants, streptozotocin, KIM-1, NGAL, omega-9 fatty acid, molecular docking, renal function